Bookmark
Forward
QuickView for Triamterene (compound)
PubChem
| Name: | Triamterene |
|---|---|
| PubChem Compound ID: | 5546 |
| Description: | A pteridine that is used as a mild diuretic. |
| Molecular formula: | C12H11N7 |
| Molecular weight: | 253.263 g/mol |
| Synonyms: |
Triamterena [INN-Spanish]; Triazide; Diucelpin; Ademine; Ademin; Hydrene; Triamterenum [INN-Latin]; Diarol; NSC77625; Dyazide.
show more » |
DrugBank
Identification
| Name: | Triamterene |
|---|---|
| Name (isomeric): | DB00384 |
| Drug Type: | small molecule |
| Description: | A pteridine that is used as a mild diuretic. |
| Synonyms: |
Triamteren
|
| Brand: | Maxzide, Diurene, Diucelpin, Ademin, Triampur, Dyrenium, Teriam, Triamteril Complex, Dytac, Urocaudal, Dyazide, Trispan, Dyren, Pterophene, Triteren, Noridyl, Pterofen, Triamteril, Ditak, Maxzide-25, Noridil, Taturil, Tri-Span, Ademine, Jatropur, Teridin, Diren |
| Brand name mixture: | Dyazide Tab(Hydrochlorothiazide + Triamterene), Penta-Triamterene HCTZ Tablets(Hydrochlorothiazide + Triamterene), Nu-Triazide Tab 50 Mg/25 Mg(Hydrochlorothiazide + Triamterene), Riva-Zide 50/25mg Tablets(Hydrochlorothiazide + Triamterene), Apo Triazide Tab(Hydrochlorothiazide + Triamterene), Novo-Triamzide(Hydrochlorothiazide + Triamterene), Pr... show more » |
| Category: | Potassium-sparing Diuretics, Diuretics |
| CAS number: | 396-01-0 |
Pharmacology
| Indication: | For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism. |
|---|---|
| Pharmacology: | Triamterene, a relatively weak, potassium-sparing diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene is similar in action to amiloride but, unlike amiloride, increases the urinary excretion of magnesium. |
| Mechanism of Action: |
Triamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. As sodium reabsorption is inhibited, this increases the osmolarity in the nephron lumen and decreases the osmolarity of the interstitium. Since sodium concent...
show more » |
| Absorption: | Rapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine. |
| Protein binding: | 55-67% (93% for the OH-TA-ester metabolite) |
| Biotransformation: | Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels. |
| Half Life: | 255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration. |
| Clearance: | 4.5 l/min [total plasma clearance] 0.22 l/kg [renal plasma clearance] |
| Toxicity: | In the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD50 in mice is 380 mg/kg. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
